Chalcogen Attached Directly To Ring Nitrogen Of The Five-membered Hetero Ring By Nonionic Bonding (e.g., Pyrrolidine-n-oxides, Etc.) Patents (Class 548/542)
  • Patent number: 10273317
    Abstract: A polymer having N-functional imide groups is prepared from reactants that include: (a) an ethylenically unsaturated anhydride or diacid monomer; (b) at least one co-monomer that is different from (a) having an ethylenically unsaturated group that is reactive with (a); and at least one compound reactive with the anhydride or diacid functional groups of (a) that is represented by Chemical Formula I: H2N—R1. With respect to Chemical Formula I, R1 is selected from NH2 or OH. Pigment dispersions and coating compositions are also prepared with the polymers having N-functional imide groups.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: April 30, 2019
    Assignee: PPG Industries Ohio, Inc.
    Inventors: Jonathan Paul Breon, Hongying Zhou, Brian Thomas Dillon, Simion Coca
  • Patent number: 10000455
    Abstract: A method reduces oxidative stress or endothelial dysfunction in a mammal. The method includes administering to the mammal a compound of formula I: or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt of the compound.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: June 19, 2018
    Assignee: Salzman Group, Inc.
    Inventors: Andrew Lurie Salzman, Prakash Jagtap, Garry John Southan
  • Patent number: 9353057
    Abstract: Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.
    Type: Grant
    Filed: January 15, 2013
    Date of Patent: May 31, 2016
    Assignee: XenoPort, Inc.
    Inventors: Mark A. Gallop, Xuedong Dai, Randall A. Scheuerman, Stephen P. Raillard, Suresh K. Manthati, Fenmei Yao, Thu Phan, Maria Ludwikow, Ge Peng, Seema Bhat
  • Patent number: 9206123
    Abstract: The present invention provides prodrugs of compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating plasma kallikrein dependent diseases or conditions, for example, diabetic macular edema, with the prodrugs having the formula:
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: December 8, 2015
    Inventors: Sukanto Sinha, Tamie Jo Chilcote
  • Patent number: 9040723
    Abstract: The present invention relates to methods of synthesizing oligomeric compounds, and more particularly, to methods of synthesizing oligomer compounds comprising polyethylene glycol moieties. The present invention provides improved methods for synthesizing oligomers comprising polyethylene glycol moieties. Methods according to embodiments of the present invention may utilize reaction conditions that are milder, efficacious than those taught by conventional methods.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: May 26, 2015
    Assignee: BIOCON LIMITED
    Inventors: Reena Vijayaraghavan, Srinivas Pullela Venkata, Chandrashekar Aswathanarayanappa
  • Publication number: 20150126744
    Abstract: This disclosure relates to new metal complexes, such as compounds of Formula 1, and their application in olefin or alkyne metathesis and to methods of carrying out olefin metathesis reactions.
    Type: Application
    Filed: December 12, 2014
    Publication date: May 7, 2015
    Inventors: Krzysztof Skowerski, Michal Bieniek
  • Publication number: 20150080364
    Abstract: Provided herein are carbamate compounds which may be useful in the treatment of for example, pain, solid tumors and/or obesity.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 19, 2015
    Applicants: Abide Therapeutics, Inc., The Scripps Research Insititute
    Inventors: Justin S. Cisar, Cheryl A. Grice, Todd K. Jones, Dong-Hui Wang, Olivia Weber, Benjamin F. Cravatt, Micah J. Niphakis, Armand Cognetta, Jae Won Chang
  • Publication number: 20150065497
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: August 5, 2014
    Publication date: March 5, 2015
    Inventors: Sara S. Hadida Ruah, Mark T. Miller, Brian Bear, Jason McCartney, Peter D.J. Grootenhuis
  • Patent number: 8969401
    Abstract: Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: March 3, 2015
    Assignee: 4SC AG
    Inventors: Thomas Maier, Thomas Beckers, Thomas Baer, Petra Gimmnich, Frank Dullweber, Matthias Vennemann
  • Publication number: 20150057449
    Abstract: One embodiment of the invention provides polyisobutylene (PIB) oligormers that are end-functionalized with ruthenium (Ru) catalysts. Such nonpolar catalysts can be dissolved in nonpolar solvents such as heptane, or any other nonpolar solvent that is otherwise not latently biphasic (i.e., if two or more solvent components are present, they remain miscible with each other throughout the entire reaction process, from the addition of substrate through to the removal of product). Substrate that is dissolved in the nonpolar solvent with the catalyst is converted into product. The lower solubility of the product in the nonpolar solvent renders it easily removable, either by extraction with a more polar solvent or by applying physical means in cases where the product precipitates from the nonpolar solvent. In this manner the catalysts are recycled; since the catalysts remain in the nonpolar solvent, a new reaction can be initiated simply by dissolving fresh substrate into the nonpolar solvent.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 26, 2015
    Applicant: The Texas A&M University System
    Inventors: David E. Bergbreiter, Hassan S. Bazzi, Chayanant Hongfa
  • Publication number: 20140350263
    Abstract: Reagents comprising MS active, fluorescent molecules with an activated functionality for reaction with amines useful in tagging biomolecules such as N-glycans and uses thereof are taught and described.
    Type: Application
    Filed: August 13, 2014
    Publication date: November 27, 2014
    Applicant: WATERS TECHNOLOGIES CORPORATION
    Inventors: Darryl W. Brousmiche, Ying-Qing Yu, Matthew Lauber
  • Publication number: 20140350241
    Abstract: Provided herein are ruthenium complexes of Formula I, and processes of preparation thereof. Also provided are methods of their use as a metathesis catalyst.
    Type: Application
    Filed: June 6, 2014
    Publication date: November 27, 2014
    Inventors: Christophe Claude PARSY, Francois-Rene ALEXANDRE, Florence Marie-Emilie BONNATERRE, Dominique SURLERAUX
  • Patent number: 8895759
    Abstract: Methods for forming maleimide functionalized polymers are provided. In one such embodiment, a maleimide functionalized polymer is prepared in a method that includes a step of carrying out a reverse Diels-Alder reaction. Intermediates useful in the methods, as well as methods for preparing the intermediates, are also provided. Also provided are polymeric reagents, methods of using polymeric reagents, compounds and conjugates.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: November 25, 2014
    Assignee: Nektar Therapeutics
    Inventors: Samuel P. McManus, Antoni Kozlowski, Tracy L. Hutchison, Brian Bray, Xiaoming Shen
  • Publication number: 20140343070
    Abstract: A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2, R3 and R4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R5 and R6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof, or a prodrug the
    Type: Application
    Filed: August 1, 2014
    Publication date: November 20, 2014
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Masahiro Kajino, Atsushi Hasuoka, Naoki Tarui, Terufumi Takagi
  • Patent number: 8889888
    Abstract: A fluorine-containing sulfonic acid salt or a compound having a fluorine-containing sulfonic acid group, either of which having a structure represented by the following general formula (1), is provided. Such a salt or compound can act as a suitable photo-acid generator, and can form a resist pattern having excellent sensitivity, resolution and mask-dependence. [In general formula (1), R represents a substituted or unsubstituted linear or branched monovalent hydrocarbon group having 1 to 30 carbon atoms, a substituted or unsubstituted monovalent hydrocarbon group having 3 to 30 carbon atoms and a cyclic or a partially cyclic structure, a substituted or unsubstituted aryl group having 6 to 30 carbon atoms, or a substituted or unsubstituted monovalent heterocyclic organic group having 4 to 30 carbon atoms.
    Type: Grant
    Filed: July 6, 2009
    Date of Patent: November 18, 2014
    Assignee: Central Glass Company, Limited
    Inventors: Masashi Nagamori, Masaki Fujiwara, Kazunori Mori, Satoru Narizuka
  • Patent number: 8889889
    Abstract: Crosslinked polymers, methods for their preparation and use, are described in which the crosslinked polymers are formed from at least two polymer precursors, one of which is designed, upon degradation of the crosslinked polymer, to release the second polymer precursor in its original, unmodified chemical form.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: November 18, 2014
    Assignee: Confluent Surgical, Inc.
    Inventors: Rachit Ohri, Phillip Blaskovich, Joshua Kennedy, Steven L. Bennett, Arthur Driscoll
  • Publication number: 20140323742
    Abstract: Methods for preparing active carbonate esters of water-soluble polymers are provided. Also provided are other methods related to the active carbonate esters of water-soluble polymers, as well as corresponding compositions.
    Type: Application
    Filed: July 11, 2014
    Publication date: October 30, 2014
    Inventors: Antoni Kozlowski, John McKannan, Samuel P. McManus
  • Publication number: 20140315220
    Abstract: Disclosed are conjugates that can bind to one or more site on cancer cell surface, for example, surface proteins, compound specific receptors and carbohydrates that comprise the surface of specific cell types. The disclosed conjugates can thereby serve as indicators identifying the presence of cancerous tissue.
    Type: Application
    Filed: July 20, 2012
    Publication date: October 23, 2014
    Applicant: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Chaofeng Dai, Binghe Wang, Lifang Wang, Yong Chu
  • Publication number: 20140303378
    Abstract: The present invention provides a production method of a sulfonylpyrrole compound useful as a pharmaceutical product, a production method of an intermediate used for the method, and a novel intermediate. The present invention relates to a method of producing sulfonylpyrrole compound (VIII), which includes reducing compound (III) and hydrolyzing the reduced product to give compound (IV), subjecting compound (IV) to a sulfonylation reaction to give compound (VI), and subjecting compound (VI) to an amination reaction.
    Type: Application
    Filed: June 12, 2014
    Publication date: October 9, 2014
    Inventors: Tomomi IKEMOTO, Hideya MIZUFUNE, Toshiaki NAGATA, Misayo SERA, Naohiro FUKUDA, Takeshi YAMASAKI
  • Publication number: 20140296476
    Abstract: The present invention provides methods and compositions that permit controlled and prolonged drug release in vivo. The compounds are either prodrugs with tunable rates of release, or conjugates of the drug with macromolecules which exhibit tunable controlled rates of release.
    Type: Application
    Filed: March 21, 2014
    Publication date: October 2, 2014
    Inventors: Daniel V. SANTI, Gary W. ASHLEY
  • Publication number: 20140275087
    Abstract: The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 18, 2014
    Inventors: Wilhelm Amberg, Frauke Pohlki, Udo Lange, Ying X. Wang, Hongyu H. Zhao, Huan-Qiu Li, Jason T. Brewer, Irini Zanze, Justin Dietrich, Anil Vasudevan, Stevan W. Djuric, Yanbin Lao, Charles W. Hutchins
  • Publication number: 20140275086
    Abstract: The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 18, 2014
    Inventors: Wilhelm Amberg, Frauke Pohlki, Udo Lange, Ying X. Wang, Hongyu H. Zhao, Huan-Qiu Li, Jason T. Brewer, Irini Zanze, Justin Dietrich, Anil Vasudevan, Stevan W. Djuric, Yanbin Lao, Charles W. Hutchins
  • Publication number: 20140275482
    Abstract: Compounds for UV-Vis detectable incorporation of a crosslinker a hapten into a protein or macromolecules are disclosed. The compounds comprise bis heterofunctional crosslinkers or haptens containing a chromophoric group that is incorporated into the linker that is positioned between a reactive linking moiety and a biotin molecule. The incorporation of the crosslinker or hapten into a protein or other macromolecules may be detected by UV-Vis spectroscopy.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Inventor: Andrei POLUKHTIN
  • Publication number: 20140249319
    Abstract: Chemical crosslinkers and methods of their synthesis are disclosed.
    Type: Application
    Filed: March 1, 2013
    Publication date: September 4, 2014
    Inventor: Mark Quang Nguyen
  • Publication number: 20140242709
    Abstract: Reagents comprising MS active, fluorescent molecules with an activated functionality for reaction with amines useful in tagging biomolecules such as N-glycans and uses thereof are taught and described.
    Type: Application
    Filed: September 28, 2012
    Publication date: August 28, 2014
    Applicant: WATERS TECHNOLOGIES CORPORATION
    Inventors: Darryl W. Brousmiche, Ying-Qing Yu
  • Publication number: 20140243509
    Abstract: Tissue slices and whole organisms offer substantial challenges to fluorescence imaging. Autofluorescence and absorption via intrinsic chromophores, such as flavins, melanin, and hemoglobins, confound and degrade output from all fluorescent tags. An “optical window,” farther red than most autofluorescence sources and in a region of low hemoglobin and water absorbance, lies between 650 and 900 nm. This valley of relative optical clarity is an attractive target for fluorescence-based studies within tissues, intact organs, and living organisms. Novel fluorescent tags were developed herein, based upon a genetically targeted fluorogen activating protein and cognate fluorogenic dye that yields emission with a peak at 733 nm exclusively when complexed as a “fluoromodule”. This tool improves substantially over previously described far-red/NIR fluorescent proteins in terms of brightness, wavelength, and flexibility by leveraging the flexibility of synthetic chemistry to produce novel chromophores.
    Type: Application
    Filed: June 18, 2013
    Publication date: August 28, 2014
    Inventors: Subhasish K. Chakraborty, Mingrui Zhang, Alan S. Waggoner
  • Patent number: 8815935
    Abstract: The present invention is directed to novel compounds. These compounds can be useful in inhibiting the activity of protein prenyltransferases including GGTase I and/or RabGGTase. The compounds can also be used as anti-cancer therapeutics including as part of methods for treating cancer, in assays, and in kits.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: August 26, 2014
    Assignee: The Regents of the University of California
    Inventors: Ohyun Kwon, Fuyuhiko Tamanoi, Hannah Fiji, Masaru Watanabe
  • Patent number: 8785659
    Abstract: Process for the preparation of a compound of formula (I) wherein R1, R2, R3, R4, R5 and R6 have the meanings as defined in the specification, comprising the step of reacting an acrylic acid chloride compound of formula (II?): wherein R1, R2, R3, R4, R5 and R6 have the meanings as defined in the specification, with aqueous hydroxylamine and optionally converting the resulting compound into an acid addition salt thereof.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: July 22, 2014
    Assignee: 4SC AG
    Inventors: Matthias Müller, Bernd Müller, Thomas Maier
  • Patent number: 8772329
    Abstract: The present invention relates to compounds from mycelium of Antrodia cinnamomea. The present invention also relates to a composition and a method for treating or prophylaxis of hepatitis C virus (HCV) infection.
    Type: Grant
    Filed: January 28, 2008
    Date of Patent: July 8, 2014
    Assignee: Simpson Biotech Co., Ltd.
    Inventors: Chia-Chin Sheu, Masao Hattori
  • Publication number: 20140187795
    Abstract: The present invention relates to processes and intermediates for the preparation of compounds useful as CRTH2 antagonists. Compounds prepared by the processes of the invention are of Formula (AI), (All) and Compound (I).
    Type: Application
    Filed: June 17, 2011
    Publication date: July 3, 2014
    Applicant: Ironwood Pharmaceuticals, Inc.
    Inventors: James Jia, Regina Graul, Wayne C Schairer, Vishnu Karnati, Ray Forslund
  • Publication number: 20140179665
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Application
    Filed: December 9, 2013
    Publication date: June 26, 2014
    Inventors: George D. Hartman, Osvaldo A. Flores
  • Publication number: 20140179681
    Abstract: Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited configuration. Also provided are methods and pharmacophores for identifying such compounds. Other aspects provide methods or therapeutic treatment for proliferative diseases, disorders, or conditions, such as those associated with EGFR.
    Type: Application
    Filed: January 8, 2014
    Publication date: June 26, 2014
    Inventor: Joseph P. Errico
  • Publication number: 20140179011
    Abstract: Reagents comprising MS active, fluorescent molecules with an activated functionality for reaction with amines useful in tagging biomolecules such as N-glycans and uses thereof are taught and described.
    Type: Application
    Filed: February 28, 2014
    Publication date: June 26, 2014
    Applicant: Waters Technologies Corporation
    Inventors: Darryl W. Brousmiche, Ying-Qing Yu
  • Publication number: 20140179753
    Abstract: The present invention relates to compounds from Antrodia cinnamomea. The present invention also relates to a composition and a method for treating or prophylaxis of hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection.
    Type: Application
    Filed: March 5, 2014
    Publication date: June 26, 2014
    Applicant: Simpson Biotech Co., Ltd.
    Inventors: Masao HATTORI, Ali EL-HALAWANY, Megumi MIZUNO, Chia-Chin SHEU
  • Publication number: 20140163017
    Abstract: In one aspect, the invention relates to substituted (E)-N?-(1-phenylethylidene)benzohydrazide analogs, derivatives thereof, and related compounds, which are useful as inhibitors of lysine-specific histone demethylase, including LSD1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the LSD1. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: June 19, 2013
    Publication date: June 12, 2014
    Applicant: UNIVERSITY OF UTAH
    Inventors: Hariprasad Vankayalapati, Venkataswamy Sorna, Steven L. Warner, Bret Stephens, David J. Bearss, Sunil Sharma
  • Publication number: 20140155511
    Abstract: Sulfur chelated ruthenium compounds represented by the following formula: wherein M indicates the ruthenium metal bound to a benzylidene carbon; R represents C1-C7 alkyl group or optionally substituted aryl; X1 and X2 each independently represent halogen; Y1 and Y2 each independently denote unsubstituted or alkyl-substituted phenyl; and Z independently represents hydrogen, electron withdrawing or electron donating substituent, with m being an integer from 1 to 4, and processes and compositions related thereto.
    Type: Application
    Filed: July 18, 2013
    Publication date: June 5, 2014
    Inventors: N. Gabriel LEMCOFF, Amos BEN-ASULY
  • Publication number: 20140135486
    Abstract: A multi-arm polyethylene glycol (I) having different kinds of reactive groups and the uses thereof are disclosed, which is formed by polymerizing ethylene oxide with oligo-pentaerythritol as an initiator, wherein, PEG is same or different and is —(CH2CH2O)m—, the average value of m is an integer of 2-250; l is an integer of 1 or more. The method for producing the multi-arm polyethylene glycol having different kinds of reactive groups, the multi-arm polyethylene glycol active derivatives comprising linking groups X attached to PEG and terminal reactive groups F attached to X, the gels formed by the multi-arm polyethylene glycol active derivatives, the drug conjugates formed by the multi-arm polyethylene glycol active derivatives and drug molecules, and the uses thereof in preparing drugs are also disclosed.
    Type: Application
    Filed: January 21, 2014
    Publication date: May 15, 2014
    Applicant: JENKEM TECHNOLOGY CO., LTD, TIANJIN BRANCH
    Inventors: Xuan Zhao, Meina Lin
  • Publication number: 20140135503
    Abstract: The subject of the invention is process for the preparation of the prostaglandin amides of the general formula I, where in the formula the bonds marked with dotted lines may be single or double bonds, in the case of double bounds at positions 5,6 and 13,14 they may be in cis or in trans orientation, Q stands for a hydroxyl-group and Z stands for a hydroxyl- or oxo-group, R1 and R2 independently represent hydrogen atom or a straight or branched C1-10 alkyl- or aralkyl- group, optionally substituted with —ONO2 group, or an aralkyl- or aryl- group, which contains heteroatom, R3 represents a straight or branched, saturated or unsaturated C4-6 hydrocarbon group, or a C4-10 alkylcycloalkyl- or cycloalkyl- group, or an optionally with alkyl group or halogen atom substituted phenyl-, C7-10 alkylaryl- or hetaryl- group, Y represents (CH2), group or 0 atom or S atom, and where n=0-3.
    Type: Application
    Filed: May 25, 2012
    Publication date: May 15, 2014
    Applicant: CHINOIN ZRT.
    Inventors: Gábor Havasi, Tibor Kiss, Irén Hortobágyi, Zsuzsanna Kardos, István Lászlófi, Zoltán Bischof, Ádám Bódis
  • Publication number: 20140128619
    Abstract: Methods for forming maleimide functionalized polymers are provided. In one such embodiment, a maleimide functionalized polymer is prepared in a method that includes a step of carrying out a reverse Diels-Alder reaction. Intermediates useful in the methods, as well as methods for preparing the intermediates, are also provided. Also provided are polymeric reagents, methods of using polymeric reagents, compounds and conjugates.
    Type: Application
    Filed: January 13, 2014
    Publication date: May 8, 2014
    Applicant: Nektar Therapeutics
    Inventors: Samuel P. McManus, Antoni Kozlowski, Tracy L. Hutchison, Brian Bray, Xiaoming Shen
  • Publication number: 20140121371
    Abstract: This disclosure relates to processes and reagents for making diaryliodonium salts, which are useful for the preparation of fluorinated, iodinated, astatinated and radiofluorinated aromatic compounds.
    Type: Application
    Filed: October 25, 2013
    Publication date: May 1, 2014
    Applicant: Ground Fluor Pharmaceuticals, Inc.
    Inventor: Stephen G. DiMagno
  • Patent number: 8703968
    Abstract: The present invention relates to compounds from Antrodia cinnamomea. The present invention also relates to a composition and a method for treating or prophylaxis of hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: April 22, 2014
    Assignee: Simpson Biotech Co., Ltd.
    Inventors: Masao Hattori, Ali El-Halawany, Megumi Mizuno, Chia-Chin Sheu
  • Publication number: 20140107349
    Abstract: The present invention provides among other things methods for preparing polymeric reagents, wherein the method comprises (a) providing an aromatic moiety bearing a hydroxy group, a first amino group and a second amino group; (b) reacting a functional group reagent with the hydroxy group to result in a hydroxy group bearing a functional group capable of reacting with an amino group of an active agent and resulting in a hydrolyzable carbamate; and (c) reacting a plurality of poly(alkylene glycol) water-soluble polymers bearing a reactive group with the first amino group and second amino group to result in (i) a first amino group bearing a water-soluble polymer through a spacer moiety, and (ii) a second amino group bearing a second water-soluble polymer through a spacer moiety.
    Type: Application
    Filed: December 17, 2013
    Publication date: April 17, 2014
    Applicant: Nektar Therapeutics
    Inventors: Michael D. Bentley, Sean M. Culbertson, Samuel P. McManus
  • Publication number: 20140093450
    Abstract: Described is a pretargeting method, and related kits, for targeted medical imaging and/or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other an E-cyclooctene which has a flattened structure as a result of the position of at least two exocyclic bonds.
    Type: Application
    Filed: May 7, 2012
    Publication date: April 3, 2014
    Applicant: KONINKLIJKE PHILIPS N.V.
    Inventors: Marc Stefan Robillard, Johan Lub, Raffaella Rossin, Sandra Martina Van Ben Bosch, Ronny Mathieu Versteegen
  • Publication number: 20140093935
    Abstract: Mitigation of photo-induced damage in excitation illuminated reactions and analyses utilizing such reactions results in an enhanced performance for the reactions and the analyses. There is provided a novel class of triplet-state quenchers for mitigating photo-induced damage which are both simple in structure and effective at preventing and/or reducing photo-induced damage to reaction components of excitation illuminated reaction mixtures. Also provided are methods of using the compounds of the invention, devices and kits incorporating the compounds of the invention.
    Type: Application
    Filed: September 27, 2013
    Publication date: April 3, 2014
    Applicant: Pacific Biosciences of California, Inc.
    Inventors: Gene Shen, Andrei Fedorov, Wei-Chuan Sun, Stephen Yue
  • Publication number: 20140088308
    Abstract: Chelating monomers and fluoride-releasing compositions are disclosed that may be incorporated into dental composite restorative materials, dental bonding agents or other dental materials, to produce materials with high fluoride release rates, and high fluoride recharge capability. Such dental restorative materials may help reduce the level of dental caries in patients, particularly the level of caries occurring on the margins of the restorative materials.
    Type: Application
    Filed: November 12, 2013
    Publication date: March 27, 2014
    Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Xiaoming Xu, Shailaja Jayaramachandran
  • Publication number: 20140081012
    Abstract: Pharmaceutical, chemical and biological agents containing a reversible disulfide linker are described. These agents can also be covalently bound or contained in delivery vehicles for delivering the agents to desired targets or areas. Also described are delivery vehicles which contain an agent having a reversible disulfide linker and to vehicles that are covalently linked to the agent containing a reversible disulfide linker. The modifications described herein can modify properties of the agents and vehicles, thereby providing desired solubility, stability, hydrophobicity and targeting while the reversibility of the linker can leave the agent to which it is attached free from residual chemical groups after being reduced.
    Type: Application
    Filed: February 15, 2012
    Publication date: March 20, 2014
    Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Joseph M. DeSimone, Mary Napier, Jin Wang, Jing Xu, Shaomin Tian, Stuart Dunn
  • Publication number: 20140081010
    Abstract: This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.
    Type: Application
    Filed: September 12, 2013
    Publication date: March 20, 2014
    Applicant: WYETH LLC
    Inventors: Justin Keith MORAN, Jianxin GU
  • Patent number: 8658434
    Abstract: The present invention relates to fluorescent pyrene dyes in general. The present invention provides a wide range of fluorescent dyes and kits containing the same, which are applicable for labeling a variety of biomolecules, cells and microorganisms. The present invention also provides various methods of using the fluorescent dyes for research and development, forensic identification, environmental studies, diagnosis, prognosis, and/or treatment of disease conditions.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: February 25, 2014
    Assignee: Biotium, Inc.
    Inventors: Fei Mao, Wai-Yee Leung, Ching-Ying Cheung
  • Publication number: 20140031562
    Abstract: A method of performing a chemical reaction includes reacting an allyl donor and a substrate in a reaction mixture, and forming a homoallylic alcohol in the reaction mixture. The substrate may be an aldehyde or a hemiacetal. The reaction mixture includes a ruthenium catalyst, carbon monoxide at a level of at least 1 equivalent relative to the substrate, and water at a level of at least 1 equivalent relative to the substrate, and an amine at a level of from 0 to 0.5 equivalent relative to the substrate. The reaction mixture may also include a halide, and the equivalents of the amine may be similar to those of the halide. The reacting includes maintaining the reaction mixture at a temperature of at least 40° C. The method may be catalytic in metal, environmentally benign, amenable to large-scale applications, and applicable to a wide range of substrates.
    Type: Application
    Filed: August 28, 2009
    Publication date: January 30, 2014
    Applicant: The Board of Trustees of the University of Illinoi
    Inventors: Scott E. Denmark, Selena Milicevic, Son T. Nguyen
  • Publication number: 20140005408
    Abstract: This disclosure relates to new metal complexes, such as compounds of Formula 1, and their application in olefin or alkyne metathesis and to methods of carrying out olefin metathesis reactions.
    Type: Application
    Filed: June 18, 2013
    Publication date: January 2, 2014
    Applicant: APEIRON SYNTHESIS S.A.
    Inventors: Krzysztof Skowerski, Michal Bieniek